ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Carrier Screening for Genetic Conditions Market Research Report 2026
Published Date: 2026-03-06
|
Report Code: QYRE-Auto-21Y20124
Home | Market Reports | Health| Medical Facilities & Services| Medical Procedures
Global Carrier Screening for Genetic Conditions Market Research Report 2026
BUY CHAPTERS

Global Carrier Screening for Genetic Conditions Market Research Report 2026

Code: QYRE-Auto-21Y20124
Report
2026-03-06
Pages:180
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
PARTNERS
Thermo Fisher Scientific
Eurofins Scientific
Illumina Inc
LabCorp
Quest Diagnostics
MedGenome
Myriad Genetics
Natera
OPKO Health
23andMe
Mayo Clinic Laboratories
Baylor Genetics
GeneDx
Fulgent Genetics
NxGen MDx
Sonic Genetics
Ambry Genetics
PreventionGenetics
DiaSorin
SYNLAB
BGI Genomics
Berry Genomics
Annaroad
Jiajian Medical Testing
GENESKY
Weihansi Biomedical Technology

Carrier Screening for Genetic Conditions Market Size

The global Carrier Screening for Genetic Conditions market was valued at US$ 2614 million in 2025 and is anticipated to reach US$ 4814 million by 2032, at a CAGR of 9.2% from 2026 to 2032.

Carrier Screening for Genetic Conditions Market

Carrier Screening for Genetic Conditions Market

Carrier Screening for Genetic Conditions is a genetic testing approach used to determine whether an individual carries a gene variant associated with inherited disorders that may be passed on to offspring. Carriers typically do not show symptoms of the condition but can transmit the altered gene to their children, particularly in autosomal recessive or X-linked inheritance patterns. The screening is commonly performed before or during pregnancy to assess reproductive risk, support informed family planning decisions, and guide further diagnostic or counseling steps when both partners are identified as carriers of the same genetic condition.
The North American market for Carrier Screening for Genetic Conditions is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Carrier Screening for Genetic Conditions is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Carrier Screening for Genetic Conditions in Couple is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Carrier Screening for Genetic Conditions include Thermo Fisher Scientific, Eurofins Scientific, Illumina, Labcorp, Quest Diagnostics, MedGenome, Myriad Genetics, Natera, OPKO Health, 23andMe, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Carrier Screening for Genetic Conditions market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Carrier Screening for Genetic Conditions. The Carrier Screening for Genetic Conditions market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Carrier Screening for Genetic Conditions market comprehensively. Regional market sizes by Type, by Application, by Screening Timing, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Carrier Screening for Genetic Conditions manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Carrier Screening for Genetic Conditions Market Report

Report Metric Details
Report Name Carrier Screening for Genetic Conditions Market
Accounted market size in 2025 US$ 2614 million
Forecasted market size in 2032 US$ 4814 million
CAGR 9.2%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • NGS
  • Whole Exome Sequencing
  • Others
Segment by Screening Timing
  • Preconception Screening
  • Prenatal Screening
Segment by Screening Scope
  • Single-condition Screening
  • Targeted multi-condition Screening
Segment by Application
  • Couple
  • Individual
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Thermo Fisher Scientific, Eurofins Scientific, Illumina, Labcorp, Quest Diagnostics, MedGenome, Myriad Genetics, Natera, OPKO Health, 23andMe, Mayo Clinic Laboratories, Baylor Genetics, GeneDx, Fulgent Genetics, NxGen MDx, Sonic Genetics, Ambry Genetics, PreventionGenetics, DiaSorin, SYNLAB, BGI Genomics, Berry Genomics, Annaroad, Jiajian Medical Testing, Genesky, Weihansi Biomedical Technology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Screening Timing, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Carrier Screening for Genetic Conditions companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Carrier Screening for Genetic Conditions Market growing?

Ans: The Carrier Screening for Genetic Conditions Market witnessing a CAGR of 9.2% during the forecast period 2026-2032.

What is the Carrier Screening for Genetic Conditions Market size in 2032?

Ans: The Carrier Screening for Genetic Conditions Market size in 2032 will be US$ 4814 million.

Who are the main players in the Carrier Screening for Genetic Conditions Market report?

Ans: The main players in the Carrier Screening for Genetic Conditions Market are Thermo Fisher Scientific, Eurofins Scientific, Illumina, Labcorp, Quest Diagnostics, MedGenome, Myriad Genetics, Natera, OPKO Health, 23andMe, Mayo Clinic Laboratories, Baylor Genetics, GeneDx, Fulgent Genetics, NxGen MDx, Sonic Genetics, Ambry Genetics, PreventionGenetics, DiaSorin, SYNLAB, BGI Genomics, Berry Genomics, Annaroad, Jiajian Medical Testing, Genesky, Weihansi Biomedical Technology

What are the Application segmentation covered in the Carrier Screening for Genetic Conditions Market report?

Ans: The Applications covered in the Carrier Screening for Genetic Conditions Market report are Couple, Individual

What are the Type segmentation covered in the Carrier Screening for Genetic Conditions Market report?

Ans: The Types covered in the Carrier Screening for Genetic Conditions Market report are NGS, Whole Exome Sequencing, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Carrier Screening for Genetic Conditions Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 NGS
1.2.3 Whole Exome Sequencing
1.2.4 Others
1.3 Market by Screening Timing
1.3.1 Global Carrier Screening for Genetic Conditions Market Size Growth Rate by Screening Timing: 2021 vs 2025 vs 2032
1.3.2 Preconception Screening
1.3.3 Prenatal Screening
1.4 Market by Screening Scope
1.4.1 Global Carrier Screening for Genetic Conditions Market Size Growth Rate by Screening Scope: 2021 vs 2025 vs 2032
1.4.2 Single-condition Screening
1.4.3 Targeted multi-condition Screening
1.5 Market by Application
1.5.1 Global Carrier Screening for Genetic Conditions Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Couple
1.5.3 Individual
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Carrier Screening for Genetic Conditions Market Perspective (2021–2032)
2.2 Global Carrier Screening for Genetic Conditions Growth Trends by Region
2.2.1 Global Carrier Screening for Genetic Conditions Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Carrier Screening for Genetic Conditions Historic Market Size by Region (2021–2026)
2.2.3 Carrier Screening for Genetic Conditions Forecasted Market Size by Region (2027–2032)
2.3 Carrier Screening for Genetic Conditions Market Dynamics
2.3.1 Carrier Screening for Genetic Conditions Industry Trends
2.3.2 Carrier Screening for Genetic Conditions Market Drivers
2.3.3 Carrier Screening for Genetic Conditions Market Challenges
2.3.4 Carrier Screening for Genetic Conditions Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Carrier Screening for Genetic Conditions Players by Revenue
3.1.1 Global Top Carrier Screening for Genetic Conditions Players by Revenue (2021–2026)
3.1.2 Global Carrier Screening for Genetic Conditions Revenue Market Share by Players (2021–2026)
3.2 Global Top Carrier Screening for Genetic Conditions Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Carrier Screening for Genetic Conditions Revenue
3.4 Global Carrier Screening for Genetic Conditions Market Concentration Ratio
3.4.1 Global Carrier Screening for Genetic Conditions Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Carrier Screening for Genetic Conditions Revenue in 2025
3.5 Global Key Players of Carrier Screening for Genetic Conditions Head Offices and Areas Served
3.6 Global Key Players of Carrier Screening for Genetic Conditions, Products and Applications
3.7 Global Key Players of Carrier Screening for Genetic Conditions, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Carrier Screening for Genetic Conditions Breakdown Data by Type
4.1 Global Carrier Screening for Genetic Conditions Historic Market Size by Type (2021–2026)
4.2 Global Carrier Screening for Genetic Conditions Forecasted Market Size by Type (2027–2032)
5 Carrier Screening for Genetic Conditions Breakdown Data by Application
5.1 Global Carrier Screening for Genetic Conditions Historic Market Size by Application (2021–2026)
5.2 Global Carrier Screening for Genetic Conditions Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Carrier Screening for Genetic Conditions Market Size (2021–2032)
6.2 North America Carrier Screening for Genetic Conditions Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Carrier Screening for Genetic Conditions Market Size by Country (2021–2026)
6.4 North America Carrier Screening for Genetic Conditions Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Carrier Screening for Genetic Conditions Market Size (2021–2032)
7.2 Europe Carrier Screening for Genetic Conditions Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Carrier Screening for Genetic Conditions Market Size by Country (2021–2026)
7.4 Europe Carrier Screening for Genetic Conditions Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Carrier Screening for Genetic Conditions Market Size (2021–2032)
8.2 Asia-Pacific Carrier Screening for Genetic Conditions Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Carrier Screening for Genetic Conditions Market Size by Region (2021–2026)
8.4 Asia-Pacific Carrier Screening for Genetic Conditions Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Carrier Screening for Genetic Conditions Market Size (2021–2032)
9.2 Latin America Carrier Screening for Genetic Conditions Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Carrier Screening for Genetic Conditions Market Size by Country (2021–2026)
9.4 Latin America Carrier Screening for Genetic Conditions Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Carrier Screening for Genetic Conditions Market Size (2021–2032)
10.2 Middle East & Africa Carrier Screening for Genetic Conditions Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Carrier Screening for Genetic Conditions Market Size by Country (2021–2026)
10.4 Middle East & Africa Carrier Screening for Genetic Conditions Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Carrier Screening for Genetic Conditions Introduction
11.1.4 Thermo Fisher Scientific Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Eurofins Scientific
11.2.1 Eurofins Scientific Company Details
11.2.2 Eurofins Scientific Business Overview
11.2.3 Eurofins Scientific Carrier Screening for Genetic Conditions Introduction
11.2.4 Eurofins Scientific Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.2.5 Eurofins Scientific Recent Development
11.3 Illumina
11.3.1 Illumina Company Details
11.3.2 Illumina Business Overview
11.3.3 Illumina Carrier Screening for Genetic Conditions Introduction
11.3.4 Illumina Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.3.5 Illumina Recent Development
11.4 Labcorp
11.4.1 Labcorp Company Details
11.4.2 Labcorp Business Overview
11.4.3 Labcorp Carrier Screening for Genetic Conditions Introduction
11.4.4 Labcorp Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.4.5 Labcorp Recent Development
11.5 Quest Diagnostics
11.5.1 Quest Diagnostics Company Details
11.5.2 Quest Diagnostics Business Overview
11.5.3 Quest Diagnostics Carrier Screening for Genetic Conditions Introduction
11.5.4 Quest Diagnostics Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.5.5 Quest Diagnostics Recent Development
11.6 MedGenome
11.6.1 MedGenome Company Details
11.6.2 MedGenome Business Overview
11.6.3 MedGenome Carrier Screening for Genetic Conditions Introduction
11.6.4 MedGenome Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.6.5 MedGenome Recent Development
11.7 Myriad Genetics
11.7.1 Myriad Genetics Company Details
11.7.2 Myriad Genetics Business Overview
11.7.3 Myriad Genetics Carrier Screening for Genetic Conditions Introduction
11.7.4 Myriad Genetics Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.7.5 Myriad Genetics Recent Development
11.8 Natera
11.8.1 Natera Company Details
11.8.2 Natera Business Overview
11.8.3 Natera Carrier Screening for Genetic Conditions Introduction
11.8.4 Natera Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.8.5 Natera Recent Development
11.9 OPKO Health
11.9.1 OPKO Health Company Details
11.9.2 OPKO Health Business Overview
11.9.3 OPKO Health Carrier Screening for Genetic Conditions Introduction
11.9.4 OPKO Health Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.9.5 OPKO Health Recent Development
11.10 23andMe
11.10.1 23andMe Company Details
11.10.2 23andMe Business Overview
11.10.3 23andMe Carrier Screening for Genetic Conditions Introduction
11.10.4 23andMe Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.10.5 23andMe Recent Development
11.11 Mayo Clinic Laboratories
11.11.1 Mayo Clinic Laboratories Company Details
11.11.2 Mayo Clinic Laboratories Business Overview
11.11.3 Mayo Clinic Laboratories Carrier Screening for Genetic Conditions Introduction
11.11.4 Mayo Clinic Laboratories Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.11.5 Mayo Clinic Laboratories Recent Development
11.12 Baylor Genetics
11.12.1 Baylor Genetics Company Details
11.12.2 Baylor Genetics Business Overview
11.12.3 Baylor Genetics Carrier Screening for Genetic Conditions Introduction
11.12.4 Baylor Genetics Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.12.5 Baylor Genetics Recent Development
11.13 GeneDx
11.13.1 GeneDx Company Details
11.13.2 GeneDx Business Overview
11.13.3 GeneDx Carrier Screening for Genetic Conditions Introduction
11.13.4 GeneDx Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.13.5 GeneDx Recent Development
11.14 Fulgent Genetics
11.14.1 Fulgent Genetics Company Details
11.14.2 Fulgent Genetics Business Overview
11.14.3 Fulgent Genetics Carrier Screening for Genetic Conditions Introduction
11.14.4 Fulgent Genetics Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.14.5 Fulgent Genetics Recent Development
11.15 NxGen MDx
11.15.1 NxGen MDx Company Details
11.15.2 NxGen MDx Business Overview
11.15.3 NxGen MDx Carrier Screening for Genetic Conditions Introduction
11.15.4 NxGen MDx Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.15.5 NxGen MDx Recent Development
11.16 Sonic Genetics
11.16.1 Sonic Genetics Company Details
11.16.2 Sonic Genetics Business Overview
11.16.3 Sonic Genetics Carrier Screening for Genetic Conditions Introduction
11.16.4 Sonic Genetics Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.16.5 Sonic Genetics Recent Development
11.17 Ambry Genetics
11.17.1 Ambry Genetics Company Details
11.17.2 Ambry Genetics Business Overview
11.17.3 Ambry Genetics Carrier Screening for Genetic Conditions Introduction
11.17.4 Ambry Genetics Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.17.5 Ambry Genetics Recent Development
11.18 PreventionGenetics
11.18.1 PreventionGenetics Company Details
11.18.2 PreventionGenetics Business Overview
11.18.3 PreventionGenetics Carrier Screening for Genetic Conditions Introduction
11.18.4 PreventionGenetics Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.18.5 PreventionGenetics Recent Development
11.19 DiaSorin
11.19.1 DiaSorin Company Details
11.19.2 DiaSorin Business Overview
11.19.3 DiaSorin Carrier Screening for Genetic Conditions Introduction
11.19.4 DiaSorin Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.19.5 DiaSorin Recent Development
11.20 SYNLAB
11.20.1 SYNLAB Company Details
11.20.2 SYNLAB Business Overview
11.20.3 SYNLAB Carrier Screening for Genetic Conditions Introduction
11.20.4 SYNLAB Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.20.5 SYNLAB Recent Development
11.21 BGI Genomics
11.21.1 BGI Genomics Company Details
11.21.2 BGI Genomics Business Overview
11.21.3 BGI Genomics Carrier Screening for Genetic Conditions Introduction
11.21.4 BGI Genomics Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.21.5 BGI Genomics Recent Development
11.22 Berry Genomics
11.22.1 Berry Genomics Company Details
11.22.2 Berry Genomics Business Overview
11.22.3 Berry Genomics Carrier Screening for Genetic Conditions Introduction
11.22.4 Berry Genomics Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.22.5 Berry Genomics Recent Development
11.23 Annaroad
11.23.1 Annaroad Company Details
11.23.2 Annaroad Business Overview
11.23.3 Annaroad Carrier Screening for Genetic Conditions Introduction
11.23.4 Annaroad Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.23.5 Annaroad Recent Development
11.24 Jiajian Medical Testing
11.24.1 Jiajian Medical Testing Company Details
11.24.2 Jiajian Medical Testing Business Overview
11.24.3 Jiajian Medical Testing Carrier Screening for Genetic Conditions Introduction
11.24.4 Jiajian Medical Testing Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.24.5 Jiajian Medical Testing Recent Development
11.25 Genesky
11.25.1 Genesky Company Details
11.25.2 Genesky Business Overview
11.25.3 Genesky Carrier Screening for Genetic Conditions Introduction
11.25.4 Genesky Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.25.5 Genesky Recent Development
11.26 Weihansi Biomedical Technology
11.26.1 Weihansi Biomedical Technology Company Details
11.26.2 Weihansi Biomedical Technology Business Overview
11.26.3 Weihansi Biomedical Technology Carrier Screening for Genetic Conditions Introduction
11.26.4 Weihansi Biomedical Technology Revenue in Carrier Screening for Genetic Conditions Business (2021–2026)
11.26.5 Weihansi Biomedical Technology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
PARTNERS
Thermo Fisher Scientific
Eurofins Scientific
Illumina Inc
LabCorp
Quest Diagnostics
MedGenome
Myriad Genetics
Natera
OPKO Health
23andMe
Mayo Clinic Laboratories
Baylor Genetics
GeneDx
Fulgent Genetics
NxGen MDx
Sonic Genetics
Ambry Genetics
PreventionGenetics
DiaSorin
SYNLAB
BGI Genomics
Berry Genomics
Annaroad
Jiajian Medical Testing
GENESKY
Weihansi Biomedical Technology
List of Tables
 Table 1. Global Carrier Screening for Genetic Conditions Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of NGS
 Table 3. Key Players of Whole Exome Sequencing
 Table 4. Key Players of Others
 Table 5. Global Carrier Screening for Genetic Conditions Market Size Growth Rate by Screening Timing (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Key Players of Preconception Screening
 Table 7. Key Players of Prenatal Screening
 Table 8. Global Carrier Screening for Genetic Conditions Market Size Growth Rate by Screening Scope (US$ Million): 2021 vs 2025 vs 2032
 Table 9. Key Players of Single-condition Screening
 Table 10. Key Players of Targeted multi-condition Screening
 Table 11. Global Carrier Screening for Genetic Conditions Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 12. Global Carrier Screening for Genetic Conditions Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 13. Global Carrier Screening for Genetic Conditions Market Size by Region (US$ Million), 2021–2026
 Table 14. Global Carrier Screening for Genetic Conditions Market Share by Region (2021–2026)
 Table 15. Global Carrier Screening for Genetic Conditions Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 16. Global Carrier Screening for Genetic Conditions Market Share by Region (2027–2032)
 Table 17. Carrier Screening for Genetic Conditions Market Trends
 Table 18. Carrier Screening for Genetic Conditions Market Drivers
 Table 19. Carrier Screening for Genetic Conditions Market Challenges
 Table 20. Carrier Screening for Genetic Conditions Market Restraints
 Table 21. Global Carrier Screening for Genetic Conditions Revenue by Players (US$ Million), 2021–2026
 Table 22. Global Carrier Screening for Genetic Conditions Market Share by Players (2021–2026)
 Table 23. Global Top Carrier Screening for Genetic Conditions Players by Tier (Tier 1, Tier 2, and Tier 3), based on Carrier Screening for Genetic Conditions Revenue, 2025
 Table 24. Ranking of Global Top Carrier Screening for Genetic Conditions Companies by Revenue (US$ Million) in 2025
 Table 25. Global 5 Largest Players Market Share by Carrier Screening for Genetic Conditions Revenue (CR5 and HHI), 2021–2026
 Table 26. Global Key Players of Carrier Screening for Genetic Conditions, Headquarters and Area Served
 Table 27. Global Key Players of Carrier Screening for Genetic Conditions, Products and Applications
 Table 28. Global Key Players of Carrier Screening for Genetic Conditions, Date of General Availability (GA)
 Table 29. Mergers and Acquisitions, Expansion Plans
 Table 30. Global Carrier Screening for Genetic Conditions Market Size by Type (US$ Million), 2021–2026
 Table 31. Global Carrier Screening for Genetic Conditions Revenue Market Share by Type (2021–2026)
 Table 32. Global Carrier Screening for Genetic Conditions Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 33. Global Carrier Screening for Genetic Conditions Revenue Market Share by Type (2027–2032)
 Table 34. Global Carrier Screening for Genetic Conditions Market Size by Application (US$ Million), 2021–2026
 Table 35. Global Carrier Screening for Genetic Conditions Revenue Market Share by Application (2021–2026)
 Table 36. Global Carrier Screening for Genetic Conditions Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 37. Global Carrier Screening for Genetic Conditions Revenue Market Share by Application (2027–2032)
 Table 38. North America Carrier Screening for Genetic Conditions Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 39. North America Carrier Screening for Genetic Conditions Market Size by Country (US$ Million), 2021–2026
 Table 40. North America Carrier Screening for Genetic Conditions Market Size by Country (US$ Million), 2027–2032
 Table 41. Europe Carrier Screening for Genetic Conditions Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 42. Europe Carrier Screening for Genetic Conditions Market Size by Country (US$ Million), 2021–2026
 Table 43. Europe Carrier Screening for Genetic Conditions Market Size by Country (US$ Million), 2027–2032
 Table 44. Asia-Pacific Carrier Screening for Genetic Conditions Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 45. Asia-Pacific Carrier Screening for Genetic Conditions Market Size by Region (US$ Million), 2021–2026
 Table 46. Asia-Pacific Carrier Screening for Genetic Conditions Market Size by Region (US$ Million), 2027–2032
 Table 47. Latin America Carrier Screening for Genetic Conditions Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 48. Latin America Carrier Screening for Genetic Conditions Market Size by Country (US$ Million), 2021–2026
 Table 49. Latin America Carrier Screening for Genetic Conditions Market Size by Country (US$ Million), 2027–2032
 Table 50. Middle East & Africa Carrier Screening for Genetic Conditions Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 51. Middle East & Africa Carrier Screening for Genetic Conditions Market Size by Country (US$ Million), 2021–2026
 Table 52. Middle East & Africa Carrier Screening for Genetic Conditions Market Size by Country (US$ Million), 2027–2032
 Table 53. Thermo Fisher Scientific Company Details
 Table 54. Thermo Fisher Scientific Business Overview
 Table 55. Thermo Fisher Scientific Carrier Screening for Genetic Conditions Product
 Table 56. Thermo Fisher Scientific Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 57. Thermo Fisher Scientific Recent Development
 Table 58. Eurofins Scientific Company Details
 Table 59. Eurofins Scientific Business Overview
 Table 60. Eurofins Scientific Carrier Screening for Genetic Conditions Product
 Table 61. Eurofins Scientific Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 62. Eurofins Scientific Recent Development
 Table 63. Illumina Company Details
 Table 64. Illumina Business Overview
 Table 65. Illumina Carrier Screening for Genetic Conditions Product
 Table 66. Illumina Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 67. Illumina Recent Development
 Table 68. Labcorp Company Details
 Table 69. Labcorp Business Overview
 Table 70. Labcorp Carrier Screening for Genetic Conditions Product
 Table 71. Labcorp Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 72. Labcorp Recent Development
 Table 73. Quest Diagnostics Company Details
 Table 74. Quest Diagnostics Business Overview
 Table 75. Quest Diagnostics Carrier Screening for Genetic Conditions Product
 Table 76. Quest Diagnostics Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 77. Quest Diagnostics Recent Development
 Table 78. MedGenome Company Details
 Table 79. MedGenome Business Overview
 Table 80. MedGenome Carrier Screening for Genetic Conditions Product
 Table 81. MedGenome Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 82. MedGenome Recent Development
 Table 83. Myriad Genetics Company Details
 Table 84. Myriad Genetics Business Overview
 Table 85. Myriad Genetics Carrier Screening for Genetic Conditions Product
 Table 86. Myriad Genetics Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 87. Myriad Genetics Recent Development
 Table 88. Natera Company Details
 Table 89. Natera Business Overview
 Table 90. Natera Carrier Screening for Genetic Conditions Product
 Table 91. Natera Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 92. Natera Recent Development
 Table 93. OPKO Health Company Details
 Table 94. OPKO Health Business Overview
 Table 95. OPKO Health Carrier Screening for Genetic Conditions Product
 Table 96. OPKO Health Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 97. OPKO Health Recent Development
 Table 98. 23andMe Company Details
 Table 99. 23andMe Business Overview
 Table 100. 23andMe Carrier Screening for Genetic Conditions Product
 Table 101. 23andMe Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 102. 23andMe Recent Development
 Table 103. Mayo Clinic Laboratories Company Details
 Table 104. Mayo Clinic Laboratories Business Overview
 Table 105. Mayo Clinic Laboratories Carrier Screening for Genetic Conditions Product
 Table 106. Mayo Clinic Laboratories Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 107. Mayo Clinic Laboratories Recent Development
 Table 108. Baylor Genetics Company Details
 Table 109. Baylor Genetics Business Overview
 Table 110. Baylor Genetics Carrier Screening for Genetic Conditions Product
 Table 111. Baylor Genetics Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 112. Baylor Genetics Recent Development
 Table 113. GeneDx Company Details
 Table 114. GeneDx Business Overview
 Table 115. GeneDx Carrier Screening for Genetic Conditions Product
 Table 116. GeneDx Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 117. GeneDx Recent Development
 Table 118. Fulgent Genetics Company Details
 Table 119. Fulgent Genetics Business Overview
 Table 120. Fulgent Genetics Carrier Screening for Genetic Conditions Product
 Table 121. Fulgent Genetics Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 122. Fulgent Genetics Recent Development
 Table 123. NxGen MDx Company Details
 Table 124. NxGen MDx Business Overview
 Table 125. NxGen MDx Carrier Screening for Genetic Conditions Product
 Table 126. NxGen MDx Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 127. NxGen MDx Recent Development
 Table 128. Sonic Genetics Company Details
 Table 129. Sonic Genetics Business Overview
 Table 130. Sonic Genetics Carrier Screening for Genetic Conditions Product
 Table 131. Sonic Genetics Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 132. Sonic Genetics Recent Development
 Table 133. Ambry Genetics Company Details
 Table 134. Ambry Genetics Business Overview
 Table 135. Ambry Genetics Carrier Screening for Genetic Conditions Product
 Table 136. Ambry Genetics Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 137. Ambry Genetics Recent Development
 Table 138. PreventionGenetics Company Details
 Table 139. PreventionGenetics Business Overview
 Table 140. PreventionGenetics Carrier Screening for Genetic Conditions Product
 Table 141. PreventionGenetics Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 142. PreventionGenetics Recent Development
 Table 143. DiaSorin Company Details
 Table 144. DiaSorin Business Overview
 Table 145. DiaSorin Carrier Screening for Genetic Conditions Product
 Table 146. DiaSorin Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 147. DiaSorin Recent Development
 Table 148. SYNLAB Company Details
 Table 149. SYNLAB Business Overview
 Table 150. SYNLAB Carrier Screening for Genetic Conditions Product
 Table 151. SYNLAB Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 152. SYNLAB Recent Development
 Table 153. BGI Genomics Company Details
 Table 154. BGI Genomics Business Overview
 Table 155. BGI Genomics Carrier Screening for Genetic Conditions Product
 Table 156. BGI Genomics Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 157. BGI Genomics Recent Development
 Table 158. Berry Genomics Company Details
 Table 159. Berry Genomics Business Overview
 Table 160. Berry Genomics Carrier Screening for Genetic Conditions Product
 Table 161. Berry Genomics Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 162. Berry Genomics Recent Development
 Table 163. Annaroad Company Details
 Table 164. Annaroad Business Overview
 Table 165. Annaroad Carrier Screening for Genetic Conditions Product
 Table 166. Annaroad Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 167. Annaroad Recent Development
 Table 168. Jiajian Medical Testing Company Details
 Table 169. Jiajian Medical Testing Business Overview
 Table 170. Jiajian Medical Testing Carrier Screening for Genetic Conditions Product
 Table 171. Jiajian Medical Testing Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 172. Jiajian Medical Testing Recent Development
 Table 173. Genesky Company Details
 Table 174. Genesky Business Overview
 Table 175. Genesky Carrier Screening for Genetic Conditions Product
 Table 176. Genesky Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 177. Genesky Recent Development
 Table 178. Weihansi Biomedical Technology Company Details
 Table 179. Weihansi Biomedical Technology Business Overview
 Table 180. Weihansi Biomedical Technology Carrier Screening for Genetic Conditions Product
 Table 181. Weihansi Biomedical Technology Revenue in Carrier Screening for Genetic Conditions Business (US$ Million), 2021–2026
 Table 182. Weihansi Biomedical Technology Recent Development
 Table 183. Research Programs/Design for This Report
 Table 184. Key Data Information from Secondary Sources
 Table 185. Key Data Information from Primary Sources
 Table 186. Authors List of This Report


List of Figures
 Figure 1. Carrier Screening for Genetic Conditions Picture
 Figure 2. Global Carrier Screening for Genetic Conditions Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Carrier Screening for Genetic Conditions Market Share by Type: 2025 vs 2032
 Figure 4. NGS Features
 Figure 5. Whole Exome Sequencing Features
 Figure 6. Others Features
 Figure 7. Global Carrier Screening for Genetic Conditions Market Size Comparison by Screening Timing (US$ Million), 2021–2032
 Figure 8. Preconception Screening Features
 Figure 9. Prenatal Screening Features
 Figure 10. Global Carrier Screening for Genetic Conditions Market Size Comparison by Screening Scope (US$ Million), 2021–2032
 Figure 11. Single-condition Screening Features
 Figure 12. Targeted multi-condition Screening Features
 Figure 13. Global Carrier Screening for Genetic Conditions Market Size by Application (US$ Million), 2021–2032
 Figure 14. Global Carrier Screening for Genetic Conditions Market Share by Application: 2025 vs 2032
 Figure 15. Couple Case Studies
 Figure 16. Individual Case Studies
 Figure 17. Carrier Screening for Genetic Conditions Report Years Considered
 Figure 18. Global Carrier Screening for Genetic Conditions Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 19. Global Carrier Screening for Genetic Conditions Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 20. Global Carrier Screening for Genetic Conditions Market Share by Region: 2025 vs 2032
 Figure 21. Global Carrier Screening for Genetic Conditions Market Share by Players in 2025
 Figure 22. Global Carrier Screening for Genetic Conditions Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 23. The Top 10 and 5 Players Market Share by Carrier Screening for Genetic Conditions Revenue in 2025
 Figure 24. North America Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. North America Carrier Screening for Genetic Conditions Market Share by Country (2021–2032)
 Figure 26. United States Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. Canada Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Europe Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Europe Carrier Screening for Genetic Conditions Market Share by Country (2021–2032)
 Figure 30. Germany Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. France Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. U.K. Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. Italy Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Russia Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. Ireland Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Asia-Pacific Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Asia-Pacific Carrier Screening for Genetic Conditions Market Share by Region (2021–2032)
 Figure 38. China Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Japan Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. South Korea Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Southeast Asia Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. India Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Australia & New Zealand Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Latin America Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Latin America Carrier Screening for Genetic Conditions Market Share by Country (2021–2032)
 Figure 46. Mexico Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. Brazil Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. Middle East & Africa Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 49. Middle East & Africa Carrier Screening for Genetic Conditions Market Share by Country (2021–2032)
 Figure 50. Israel Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 51. Saudi Arabia Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 52. UAE Carrier Screening for Genetic Conditions Market Size YoY Growth (US$ Million), 2021–2032
 Figure 53. Thermo Fisher Scientific Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 54. Eurofins Scientific Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 55. Illumina Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 56. Labcorp Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 57. Quest Diagnostics Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 58. MedGenome Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 59. Myriad Genetics Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 60. Natera Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 61. OPKO Health Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 62. 23andMe Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 63. Mayo Clinic Laboratories Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 64. Baylor Genetics Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 65. GeneDx Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 66. Fulgent Genetics Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 67. NxGen MDx Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 68. Sonic Genetics Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 69. Ambry Genetics Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 70. PreventionGenetics Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 71. DiaSorin Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 72. SYNLAB Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 73. BGI Genomics Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 74. Berry Genomics Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 75. Annaroad Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 76. Jiajian Medical Testing Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 77. Genesky Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 78. Weihansi Biomedical Technology Revenue Growth Rate in Carrier Screening for Genetic Conditions Business (2021–2026)
 Figure 79. Bottom-up and Top-down Approaches for This Report
 Figure 80. Data Triangulation
 Figure 81. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions